Detalhe da pesquisa
1.
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.
Gynecol Oncol
; 178: 110-118, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37839313
2.
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
Br J Cancer
; 123(11): 1590-1598, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32913286
3.
Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.
Br J Haematol
; 178(5): 756-763, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28591409
4.
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
Invest New Drugs
; 35(1): 47-58, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27650277
5.
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
Blood
; 123(5): 632-9, 2014 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-24335104
6.
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
Am J Hematol
; 91(4): 400-5, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26800393
7.
Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
Br J Haematol
; 166(6): 920-8, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25039282
8.
Safety and pharmacodynamics of a single infusion of danavorexton in adults with obstructive sleep apnea experiencing excessive daytime sleepiness despite adequate use of CPAP.
Sleep Med
; 107: 229-235, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37244138
9.
Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia.
Sleep
; 46(9)2023 09 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36883238
10.
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor.
Clin Cancer Res
; 28(6): 1107-1116, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34980598
11.
Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy.
Haematologica
; 96(11): 1662-9, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21791470
12.
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.
Clin Cancer Res
; 27(12): 3329-3338, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33820779
13.
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Biol Blood Marrow Transplant
; 16(1): 70-7, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19733251
14.
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Br J Haematol
; 147(4): 531-4, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19725827
15.
Dose Optimization for Anticancer Drug Combinations: Maximizing Therapeutic Index via Clinical Exposure-Toxicity/Preclinical Exposure-Efficacy Modeling.
Clin Cancer Res
; 25(22): 6633-6643, 2019 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31320596
16.
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.
ESMO Open
; 3(2): e000291, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29464110
17.
Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range.
J Clin Pharmacol
; 57(9): 1183-1193, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28419486
18.
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
J Clin Oncol
; 35(31): 3538-3546, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28862883
19.
Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.
Clin Cancer Res
; 22(16): 4206-4214, 2016 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27006493
20.
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
J Clin Oncol
; 33(33): 3921-9, 2015 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-26056177